# Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

> **NCT01263379** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abeona Therapeutics, Inc** · enrollment: 12 (actual)

## Conditions studied

- Epidermolysis Bullosa Dystrophica
- Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

## Key facts

- **NCT ID:** NCT01263379
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-05
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-08-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263379, "Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01263379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*